3946 Stone Canyon Avenue
About TearClear Corp.TearClear Corp. is an early-stage, disruptive eye health technology company focused on developing a safe and reliable means of delivering preservative-free topical ophthalmic drugs from existing preserved, multi-dose systems. Co-founded by the inventor Anuj Chauhan, PhD, Professor & Associate Chair, Chemical Engineering at the University of Florida, the company is developing the unique technology to target the drugs used to treat chronic diseases where BAK is commonly used to assure sterility in multi-dose bottles. TearClear aims to address the global market of ophthalmologic drugs for glaucoma, over-the-counter (OTC) dry eye, and allergic conjunctivitis.
Co-Founder: Anuj Chauhan, PhD
Chairman of the Board: Rick Heinick
CEO: Kevin Hershfield
CTO: Richard D’Souza, PhD
Head of Clinical Development: Howard Golub, MD, PhD
11 articles about TearClear Corp.
TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%)
TearClear, an ophthalmic pharmaceutical company that transforms trusted drugs into branded best-in-class therapies, announced today that the company’s lead product, TC-002 (latanoprost ophthalmic solution 0.005%) met the primary and all secondary endpoints in the CLEAR Phase 3 pivotal trial.
TearClear announces the successful initiation of its TC-002 Latanoprost Ophthalmic Solution Phase 3 trial
TearClear, a late clinical stage ophthalmic pharmaceutical company, is pleased to announce the TC-002 Phase 3 trial has been successfully initiated.
TearClear Files Investigational New Drug (IND) Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%
TearClear, a late clinical stage ophthalmic pharmaceutical company, has filed an Investigational New Drug (IND) application to conduct a registrational study for its lead glaucoma candidate, TC-002 latanoprost ophthalmic solution, 0.005%.
TearClear continues to make progress on the development of its first-in-class platform of preservative-free topical medications.
TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of GlaucomaPrepared to file an IND in mid-2021 via the 505(b)(2) NDA pathway
TearClear, an emerging ophthalmic pharmaceutical company, announced successful completion of pre-IND meeting with the U.S. Food and Drug Administration regarding the development plan for the preservative free multi-dose delivery of a proprietary Latanoprost formulation, including the clinical study design for the registration study.
TearClear Appoints Robert Bailey to Board of DirectorsBailey’s executive experience in the Ophthalmology industry further strengthens the organization
TearClear announces the appointment of industry veteran Robert Bailey to the company’s Board of Directors.
TearClear has raised $22M in a Series B funding round. The investment will be used to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications.
TearClear appoints Dr. Amir Shojaei Chief Development OfficerShojaei brings two decades of experience in clinical pharmaceutical development
TearClear Corp., an emerging Ophthalmic Pharmaceutical Company, has announced the appointment of Amir Shojaei, Pharm.D., Ph.D., as Chief Development Officer, a major step towards planning and executing multiple clinical development and registration programs.
4/17/2020Pharma and life sciences companies boost their executive ranks and boards with this week's Movers & Shakers.
TearClear appoints Robert J. Dempsey Chief Executive OfficerTearClear to initiate global market strategy for its pharmaceutical business
TearClear, a global Ophthalmic Pharmaceutical Company, today announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear is the only pharmaceutical company to administer preservative free eye drops to the ocular surface, that are preserved safely prior to dosing. Dempsey, who has more than two decades of experience in the ophthalmic pharmaceutical industry, is expected to accelerate TearClear’s business and commercial stra
TearClear Completes $4.5 Million Series A Financing And Introduces Leadership Team Of Accomplished Ophthalmology Veterans